World Library  
Flag as Inappropriate
Email this Article

Rufinamide

Article Id: WHEBN0006552264
Reproduction Date:

Title: Rufinamide  
Author: World Heritage Encyclopedia
Language: English
Subject: ATC code N03, Valproate pivoxil, Eslicarbazepine acetate, Gabapentin enacarbil, Zonisamide
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Rufinamide

Rufinamide
Systematic (IUPAC) name
1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
Clinical data
AHFS/Drugs.com
MedlinePlus
Licence data EMA:, US FDA:
Legal status
  • Prescription only
Routes Oral
Identifiers
CAS number  N
ATC code N03
PubChem
ChemSpider  YesY
UNII  YesY
ChEMBL  N
Chemical data
Formula C10H8F2N4O 
Mol. mass 238.194
 N   

Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome[1] and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures [2] It is marketed under the brand name Banzel.[3] It is also marketed in the European Union under the brand name Inovelon.[4]

The mechanism of action of rufinamide is unknown. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels,[5] a common target for antiepileptic drugs.[6] A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability.[7] However, this action cannot explain the unique spectrum of activity of rufinamide.

References

  1. ^ Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW (August 2007). "Rufinamide: a new anti-epileptic medication". Expert Opin Pharmacother 8 (12): 1931–40.  
  2. ^ Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, Arroyo S (August 2009). "Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial". Epilepsia 50 (8): 1899–909.  
  3. ^ FDA press release - FDA Approves New Drug to Treat Severe Form of Epilepsy
  4. ^ European Public Assessment Report for rufinamide (INOVELON)
  5. ^ Rogawski, M. A. (2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research 69 (3): 273–94.  
  6. ^ Rogawski, A.; Löscher, W. (Jul 2004). "The neurobiology of antiepileptic drugs". Nature reviews. Neuroscience 5 (7): 553–564.  
  7. ^ Gilchrist, J; Dutton, S; Diaz-Bustamante, M; McPherson, A; Olivares, N; Kalia, J; Escayg, A; Bosmans, F (2014). "Nav1.1 modulation by a novel triazole compound attenuates epileptic seizures in rodents". ACS Chemical Biology 9 (5): 1204–12.  

External links

  • Drugs.com - Rufinamide
  • Epilepsy.com - Rufinamide
  • Miami Children's Brain Institute - Rufinamide
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.